Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · IEX Real-Time Price · USD
40.01
-3.32 (-7.66%)
At close: May 31, 2024, 4:00 PM
39.75
-0.26 (-0.65%)
After-hours: May 31, 2024, 7:51 PM EDT
Legend Biotech Revenue
Legend Biotech had revenue of $342.80M in the twelve months ending March 31, 2024, with 231.84% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $93.99M with 158.67% year-over-year growth. In the year 2023, Legend Biotech had annual revenue of $285.14M with 143.70% growth.
Revenue (ttm)
$342.80M
Revenue Growth
+231.84%
P/S Ratio
21.28
Revenue / Employee
$187,732
Employees
1,826
Market Cap
7.29B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 285.14M | 168.14M | 143.70% |
Dec 31, 2022 | 117.01M | 48.18M | 70.00% |
Dec 31, 2021 | 68.83M | -6.17M | -8.23% |
Dec 31, 2020 | 75.00M | 15.02M | 25.04% |
Dec 31, 2019 | 59.98M | 10.85M | 22.08% |
Dec 31, 2018 | 49.13M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bio-Rad Laboratories | 2.61B |
Exact Sciences | 2.53B |
Chemed | 2.29B |
Penumbra | 1.10B |
Repligen | 607.45M |
Ascendis Pharma | 357.63M |
LEGN News
- 4 days ago - Legend Biotech to Participate in the Jefferies Global Healthcare Conference - Business Wire
- 10 days ago - Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA - Business Wire
- 20 days ago - Legend Biotech Reports First Quarter 2024 Results and Recent Highlights - Business Wire
- 5 weeks ago - CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma - Business Wire
- 7 weeks ago - Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results - Business Wire
- 2 months ago - Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma - Business Wire
- 2 months ago - Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report - Business Wire
- 2 months ago - CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma - Business Wire